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ABSTRACT 
Rheumatoid arthritis is an autoimmune disease resulting in chronic synovial inflammation. Molecular 
imaging could be used to monitor therapy response, thus enabling tailored therapy regimens and 
enhancing therapeutic outcome. Here, we hypothesized that response to etanercept could be 
monitored by radionuclide imaging in arthritic mice. We tested three different targets namely 
fibroblast activation protein (FAP), macrophages, and integrin αvβ3. 
METHODS 
Male DBA/1J mice with collagen-induced arthritis were treated with etanercept. SPECT/CT (Single 
photon emission computed tomography/ X-ray computed tomography) scans were acquired at 1, 24 
and 48 h after injecting 111In-RGD2 (integrin αvβ3), 111In-anti-F4/80-A3-1 (anti-murine macrophage 
antibody), or 111In-28H1 (anti-FAP antibody), respectively, with nonspecific controls included. Mice 
were dissected after the last scan and scans were analyzed quantitatively and were correlated with 
macroscopic scoring. 
RESULTS 
Experimental arthritis was imaged with 111In-28H1 (anti-FAP), 111In-anti-F4/80-A3-1, and 111In-RGD2. 
Tracer uptake in joints correlated with arthritis score. Treatment decreased joint uptake of tracers; it 
decreased from 23±15 %ID/g, 8±4 %ID/g, 2±1 %ID/g to 11±11 %ID/g (p<0.001), 4±4 %ID/g (p<0.001), 
1±0.2 %ID/g (p<0.01) for 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2, respectively. Arthritis-to-
blood ratios (in mice with arthritis score 2 per joint) were higher for 111In-28H1 (5.5±1; excluding 
values over 25), 111In-anti-F4/80-A3-1 (10.4±4), and 111In-RGD2 (7.2±1) than for control 111In-DP47GS 
(0.7±0.5; p=0.002), 111In-rat IgG2b (0.5±0.2; p=0.002), or coinjection of excess RGD2, (3.5), indicating 
specific uptake of all tracers in arthritic joints. 
CONCLUSION 
111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2 can be used to specifically monitor the response to 
therapy in experimental arthritis at the molecular level. Further studies however still need to be 
carried out. 
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INTRODUCTION  
Rheumatoid arthritis is an autoimmune disease with a global prevalence of 0.24% in 2010 (1). 
Arthritis is marked by symptoms including joint pain and swelling caused by chronic inflammation in 
synovial joints and can be treated systemically or intra-articularly by either non-steroidal anti-
inflammatory drugs, corticosteroids or disease-modifying anti-rheumatic drugs (DMARDs) (2, 3). In 
addition, treatment with biologicals has been shown to be quite effective in patients. 
Because arthritis is a chronic disease characterized by disease exacerbations (4),  it has 
become crucial to develop tools to effectively monitor disease progression, prevent progressive 
destruction, and predict or monitor response to therapy, which are as important for a positive 
outcome as early diagnosis. Monitoring response to therapy could allow for the therapeutic 
schedules- aimed to reduce inflammation, relieve pain, and reduce disabilities - to be altered if 
deemed necessary. This could thus minimize unwarranted side effects and irreversible joint damage. 
This is especially pertinent for therapies such as DMARDs, where it can take several weeks to months 
for clinical improvements to show (5).  
Many cell types that play a role in joint inflammation and destruction are present in the 
synovial lining. One of the most prominent cell populations is activated fibroblast-like synoviocytes 
(6), which express fibroblast activation protein (FAP) (7) and could be imaged by microSPECT using 
radiolabeled antibodies against FAP, as shown by us recently (8). Other cell types include osteoclasts 
(9), which express integrin αvβ3 (10). Integrin αvβ3 is a much-used target for imaging tumour cells and 
angiogenesis in oncology using radiolabeled RGD peptides. Preclinically, F4/80 receptor-positive 
macrophages also play a role in arthritis pathogenesis (11). These targets have previously been 
successfully imaged by either radiolabeled RGD-based peptides (12), and an anti-F4/80-A3-1 labeled 
with In-111 (13), respectively, albeit in an oncological setting.  
Non-invasive imaging could be a great tool in determining early on whether therapies are 
successful (14, 15), yet few approaches have been aimed at a molecular level specific for arthritis. 
Here, we focused on imaging these three different targets, namely FAP, macrophages, and integrin 
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αvβ3, and determined whether they could be useful tools to monitor response to the Tumour 
Necrosis Factor (TNF) receptor fusion protein etanercept therapy in arthritic mice. These targets 
were also chosen because the treatment used here, etanercept, targets TNF, which is produced 
mainly by monocyte-macrophages, activated endothelial cells, which also express integrin αvβ3 (16), 
and synovial fibroblasts (17). 
 
MATERIALS AND METHODS 
Antibody Conjugation And RGD Peptide  
Rat anti-mouse anti-F4/80-A3-1 antibody (AbD Serotec, Kidlington, UK) and rat IgG2b (R&D 
Systems, Abingdon, UK) were dialyzed against 1:1 phosphate buffered saline (PBS, pH 7.4):water 
(1:1) to remove sodium azide. Antibodies 28H1 (anti-FAP), DP47GS (8), anti-F4/80-A3-1 and rat 
IgG2b (13), were conjugated with isothiocyanatobenzyl–diethylenetriamenepentaacetic acid (p-SCN-
Bz-DTPA) (Macrocyclics, Inc., Dallas, TX) in 0.1 M NaHCO3, pH 9.5, using a 5-fold (28H1, DP47GS) or 
10-fold (anti-F4/80-A3-1, IgG2b) molar excess of p-SCN-Bz-DTPA for 1 h at room temperature. 
Unconjugated p-SCN-Bz-DTPA was removed by dialysis against 0.25 M ammonium acetate buffer, pH 
5.5 (28H1, DP47GS) or 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.5 (anti-F4/80-A3-1, 
IgG2b). DP47GS and rat IgG2b antibodies served as isotype controls for 28H1 and anti-F4/80-A3-1, 
respectively.  
DOTA-E-[c(RGDfK)]2 (RGD2) was acquired from Peptides International, KY, USA. Here we used 
the 28H1 and DP47GS antibodies, which are non-internalizing antibodies bearing a mutation in the 
Fc effector part, preventing binding to the Fc receptor.  All buffers used were metal-free. 
The affinity of all three tracers and the immunoreactive fraction of anti-F4/80-A3-1  (75%) have been 
determined previously (8, 13, 18). The immunoreactive fraction for 111In-28H1 was 91.4% (Figure S1). 
 
Radiolabeling 
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For radiolabeling, 750 μg of DTPA-28H1 or DTPA-DP47GS was incubated with 250-320 MBq 
111InCl3 (Mallinckrodt BV, Petten, The Netherlands) in 0.1 M 2-(N-morpholino)ethanesulfonic acid 
buffer pH 5.4 (MES buffer) for 30 min at room temperature. For studies involving anti-F4/80-A3-1 or 
rat IgG2b, 280-320 MBq 111InCl3 (Mallinckrodt, Petten, the Netherlands) was added to 140 µg DTPA-
anti-F4/80-A3-1 or 125 µg rat IgG2b for 1 h at room temperature in 0.1 MES buffer pH 5.4. For 
studies involving RGD2, 8 µg DOTA-conjugated peptide, dissolved in 0.1 M MES buffer, pH 5.4, was 
incubated with 200 MBq 111InCl3 for 20 minutes at 95 °C. Unincorporated 111In was complexed by 
adding ethylenediaminetetraacetic acid (final concentration of 5 mM) after the labeling. 
Labeling efficiencies of all antibodies and the RGD2 peptide were determined by instant thin-
layer chromatography on instant thin-layer chromatography-silica gel strips (Agilent Technologies, 
Santa Clara, CA), with 0.1 M acetate buffer, pH 5.4, as the mobile phase. Labeling efficiencies were 
93%, 99%, 91%, 95%, and 99%, for 111In-28H1, 111In-DP47GS, 111In-anti-F4/80-A3-1, 111In-rat IgG2b, 
and 111In-RGD2, respectively.  Tracers were diluted with PBS (with 0.5% bovine serum albumin (BSA)) 
and unlabeled antibody or peptide was added to obtain the required antibody or peptide dose. 
 
Animal Model 
Mice (22-25g) were housed in IVC cages with 5 mice/cage in a temperature- and humidity-
controlled room with 12/12-hour light/dark cycle. Animals had unlimited access to water and food. 
Arthritis was induced in male DBA/1J mice by intradermal immunization at the tail base with 100 µg 
of bovine type II collagen (CII) in Freund’s complete adjuvant followed by an intraperitoneal (i.p.) 
booster injection of 100 µg of CII in PBS three weeks later (collagen-induced arthritis; CIA). Arthritic 
scores per paw ranged from mild to severe (Score 0 = no sign of arthritis, 0.25 = 1-2 toes red or 
swollen; 0.5 = 3-5 toes red or swollen; 1 = swollen ankle; 1.5 = swollen footpad; 2 = severe swelling 
and ankylosis). Etanercept treatment (10 mg/kg, 3x per week, i.p.) started when mice showed first 
signs of the onset of arthritis (Score ≥0.25 in one joint). Untreated arthritic mice were used as 
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control. Animal experiments were approved by the local animal welfare committee and performed 
according to national regulations. 
 
Biodistribution Studies 
In dose finding studies, arthritic male DBA/1J mice were injected intravenously (i.v.) with 
either 10 or 40 µg 111In-anti-F4/80-A3-1 or 111In-IgG2b, as done previously for 111In-28H1, and the 
biodistribution was measured by ex vivo analysis of the accumulation of the tracer in different 
organs and joints after dissection of the mice. In other biodistribution studies, treated and untreated 
male mice were injected i.v with 50 µg 111In-DTPA-28H1 or 111In-DTPA-DP47GS, 10 µg 111In-anti-
F4/80-A3-1 or 111In-rat IgG2b, or 1 µg (radiolabeled) or 50 µg (1 µg + 49 µg unlabeled) 111In-RGD2 (3-4 
MBq). At 48 h (111In-DTPA-28H1 and 111In-DTPA-DP47GS), 24 h (111In-anti-F4/80-A3-1 and 111In-rat 
IgG2b) and 1 h (111In-RGD2) after tracer injection, mice were euthanized by CO2/O2 asphyxiation. In 
total ten mice were used per group where blood, arthritic joints and major organs and tissues were 
dissected, weighed and counted in a shielded well-type gamma counter (Perkin-Elmer, Boston, MA, 
USA) to provide the %ID/g. 
 
Micro-SPECT/CT Imaging 
In imaging studies, treated and untreated male mice were injected i.v. with 50 µg 111In-
DTPA-28H1 or 111In-DTPA-DP47GS, 10 µg 111In-anti-F4/80-A3-1 or 111In-rat IgG2b, or 1 µg 
(radiolabeled) or 50 µg (1 µg + 49 µg unlabeled) 111In-RGD2 (15-21 MBq). At 48 h (111In-DTPA-28H1 
and 111In-DTPA-DP47GS), 24 h (111In-anti-F4/80-A3-1 and 111In-rat IgG2b) and 1 h (111In-RGD2) after 
tracer injection, mice were euthanized by CO2/O2 asphyxiation for ex vivo biodistribution studies 
(3/group). Mice were then scanned with the U-SPECT-II/CT scanner (MILabs, Utrecht, The 
Netherlands) in prone position. Micro-SPECT scans were acquired as 3 frames of 15 min using a 1.0 
mm pinhole ultra high sensitivity mouse collimator, followed by a CT scan for anatomic reference (65 
kV, 615 µA). Scans were reconstructed and all frames combined using software from MILabs, using 
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an ordered-subset expectation maximization algorithm, with a voxel size of 0.4 mm. For high-
resolution micro-SPECT imaging of an arthritic joint, a focal image was acquired using a 0.35 mm 
ultra-high resolution pinhole collimator at 9 frames of 18 min. Images were reconstructed to a voxel 
size of 0.125 mm without attenuation correction. 
 
Quantitative SPECT Analysis 
Reconstructed micro-SPECT scans were coregistered with CT images using Inveon Research 
Workplace software (version 3.0; Siemens Preclinical Solutions, LLC). The regions of interest were 
drawn using CT images and transferred to the SPECT data to obtain mean voxel intensities of the 
SPECT data corresponding to those regions of interest. Mean voxel intensity values were converted 
to %ID using decay correction and a standard curve (mean voxel intensity vs. kBq) acquired by 
scanning and reconstructing known In-111 activities from 15 to 310 kBq under the same conditions 
as the animal scans. 
 
Statistical Analysis 
Statistical analysis was performed using Wilcoxon signed-rank test or 2-way ANOVA with 
GraphPad Prism (version 5.03; GraphPad Software). Each paw is analyzed as an independent event. 
Spearman r correlation values between arthritis:blood values and arthritis score were calculated for 
Figure 1. Statistical significance was represented as *(p≤0.05), **(p≤0.01), and ***(p≤0.001).  
 
RESULTS 
Dosing Study Of 111In-anti-F4/80-A3-1 
The optimal dose of 111In-anti-F4/80-A3-1 in mice was determined to be 10 µg; accumulation 
in most tissues remained largely unaltered compared to 40 µg 111In-anti-F4/80-A3-1, yet the 
arthritis:blood ratio was increased (Figure S2). For instance, uptake of 10 or 40 µg 111In-anti-F4/80-
A3-1 in the blood equaled 1.4 ± 0.4 %ID/g or 2.3 ± 0.6 %ID/g, respectively. Notably, splenic uptake 
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was higher at 10 µg 111In-anti-F4/80-A3-1 (103.9 ± 6.4 %ID/g) than at 40 µg 111In-anti-F4/80-A3-1 
(34.6 ± 4.4 %ID/g). The arthritis:blood ratios were higher for 10 µg 111In-anti-F4/80-A3-1 (10.1 ± 5.2) 
compared to 40 µg 111In-anti-F4/80-A3-1 (4.6 ± 3.2) and both values were higher than for 111In-IgG2b 
, which equaled 0.3 ± 0.2 and 0.4 ± 0.3 at 10 and 40  µg, respectively (Figure S2C).                                                                                                                           
 
Etanercept Therapy 
Treatment with etanercept was successful as macroscopic scores of arthritis were lower in 
treated mice than in untreated mice (Figure S3). At day 6 after start of therapy, average arthritis 
scores were 4.0 ± 1.7 in untreated mice and 1.8 ± 1.1 in treated mice, as measured on a scale of 0-8 
per mouse (i.e. 0-2 per paw). 
 
Biodistribution Studies  
Biodistribution studies after dissection showed that uptake of 111In-28H1 (Spearman r 
0.4069; p<0.001), 111In-anti-F4/80-A3-1 (Spearman r 0.7542; p<0.0001), and 111In-RGD2 (Spearman r 
0.6527; p<0.01) was decreased in arthritic joints in mice treated with etanercept and that tracer 
uptake correlated with arthritic score (Figure 1). For instance, joint uptake of 111In-28H1 in treated 
and untreated mice averaged 11 ± 11 %ID/g (CI: 7.0-15.1) and 23 ± 15 %ID/g (CI: 17.6-29.1), 
respectively (p<0.001). Joint uptake of 111In-anti-F4/80-A3-1 decreased from 8 ± 4 %ID/g (CI: 6.8-9.3) 
to 4 ± 4  %ID/g (CI: 2.5-4.9) after treatment (p<0.001 for both tracers between treated and 
untreated) as did 111In-RGD2 uptake (from 2 ± 1 %ID/g (CI: 1.5-2.8) to 1 ± 0.2 %ID/g (CI: 0.8-1.2)) 
(p=0.0078). Uptake of all three tracers when normalized to blood (arthritis:blood values), was higher 
at each arthritic score (0.25-2) for 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2 than for controls 
111In-DP47GS, 111In-anti-ratIgG2b, and 111In-RGD2 plus unlabeled excess (Figures 1B, D, F). P values at 
arthritis score 2 (per joint) were 0.002 comparing 111In-28H1 and 111In-anti-F4/80-A3-1 to their 
controls. 
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In untreated mice, blood levels were higher, whereas femur uptake values were lower, for 
111In-DP47GS compared to 111In-28H1 (Figure S4A). Etanercept therapy resulted in lower blood 
values and higher liver values for 111In-28H1 and 111In-DP47GS compared to untreated mice (Figure 
S4A), most likely due to a mouse-anti-human IgG response. Whole body biodistribution varied 
between 111In-anti-F4/80-A3-1 and its isotype-matched control 111In-ratIgG2b with lower blood 
circulating levels and higher uptake in the spleen, liver and femur compared to blood values for 111In-
anti-F4/80-A3-1 (Figure S4B). Etanercept treatment had no effect on general biodistribution of 111In-
anti-F4/80-A3-1, 111In-ratIgG2b, 111In-RGD2 or 111In-RGD2 plus excess unlabeled (Figures S4B, C).  
Table 1 shows a summary of the arthritis:blood values obtained in biodistribution studies. 
 
Quantitative SPECT Analysis 
Arthritic joints were specifically visualized with 111In-28H1 (Figures 2, S5), 111In-anti-F4/80-
A3-1 (Figures 3 and S6), and 111In-RGD2 (Figures 4, S7). Quantitative SPECT analysis showed that 
tracer uptake within joints significantly decreased in treated animals compared to untreated 
controls (Figures 2-4). For instance, joint uptake equaled 2.0 ± 0.6 %ID, 0.6 ± 0.2 %ID and 0.2 ± 0.1 
%ID in untreated animals for 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2, respectively.  These 
values are higher than in treated animals (0.7 ± 0.8 %ID, 0.3 ± 0.2 %ID, and 0.08 ± 0.02 %ID). Uptake 
of 111In-28H1 in arthritic, untreated joints was far higher (2.0 ± 0.6 %ID) than uptake of 111In-DP47GS 
(0.8 ± 0.4 %ID) and joint uptake of 111In-anti-ratIgG2b was not significantly decreased in untreated 
versus treated mice (0.7 ± 0.4 %ID and 0.5 ± 0.4 %ID, respectively).  
Values obtained for 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2 by quantitative SPECT analysis 
correlated well with macroscopic arthritis scores (Figure S8).  
 
DISCUSSION 
The data acquired in the dosing study is consistent with the idea of the spleen and liver 
acting as an antigen sink for 111In-anti-F4/80-A3-1 due to the presence of a large number of 
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macrophages (13). Due to its short circulation time, studies involving 111In-anti-F4/80-A3-1 were 
completed at 24 hours post injection. 
Etanercept, the drug of choice in these studies, is a soluble fusion protein consisting of 
human p75 TNF-α receptor and the Fc portion of human IgG (19). It is a biological DMARD that 
inhibits binding of inflammatory cytokine TNF-α to its receptor and is often given to arthritis patients 
if other treatments are contra-indicated or withdrawn due to adverse events.  
Here, we show that the effect of etanercept on macroscopic/clinical arthritis score can not 
only be visualized non-invasively using imaging tracers that target either FAP, macrophages or 
integrins, but can also be measured quantitatively in either ex vivo biodistribution studies or 
quantitative SPECT. In previous studies, the authors did not see accumulation of any of the tracers in 
the joints of non-arthritic mice (8, 12, 13, 18). The three tracers are very different with regard to 
their targets, mechanism and pharmacokinetics; they all measure something different, so a straight 
comparison was not performed here.  
The uptake of 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2 is antigen/receptor-mediated 
as joint:blood values decreased for antibody controls or for 111In-RGD2 when competed with excess 
peptide (Figure 1). For all tracers, including the RGD peptide, the enhanced permeability and 
retention (EPR) effect did add to total tracer uptake as the nonspecific uptake of the tracer, 
displayed by total joint uptake values of 111In-DP47GS, 111In-ratIgG2b, and 111In-RGD2 plus excess, was 
altered in treated mice (Figure 1). 
Decreased antigen-mediated uptake of 111In-28H1 in arthritic joints of treated CIA mice could 
be explained by diminished expression of FAP at the site, which fits the notion of etanercept 
inducing apoptosis in activated fibroblast-like synoviocytes (20). The potential presence of anti-drug 
antibodies, as seen in arthritis cases for anti-TNF drugs, such as etanercept, (21, 22), human anti-
murine antibodies (23), or anti-human murine antibodies (24), could explain the enhanced liver 
uptake of 111In-28H1 after etanercept treatment (Figure S4A). In turn this enhanced liver uptake 
might also explain the lower uptake in joints of treated mice.  
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Decreased uptake of 111In-anti-F4/80-A3-1 in arthritic joints after treatment may also be 
explained by lowered targeted availability as etanercept has been shown to induce apoptosis in 
macrophages resident in the synovium of arthritis patients 8 weeks as well as in mononuclear cells 
from synovial fluid in vitro (25). Similar targeted-mediated responses are also thought to be 
responsible for changes in 111In-RGD2 uptake in arthritic joints after etanercept therapy by affected 
osteoclasts (26, 27) and vasculature (28). The latter option is possible, as endothelial cells have 
previously been targeted for use in imaging of inflammation (29).  
It is important to note that quantitative SPECT values (%ID) and biodistribution data (%ID/g) 
were not directly comparable in these studies, as quantitative SPECT values were derived from the 
whole paw (toe/finger to above ankle/wrist) and biodistribution data were derived from the areas 
directly surrounding the ankle/wrist. Interestingly, total non-antigen-mediated uptake of 111In-
ratIgG2b in the joint significantly decreased in treated compared to untreated CIA mice in 
biodistribution studies (Figure 1C), yet not in the quantitative SPECT studies (Figure 3C); likely due to 
a limited sensitivity of quantitative SPECT. 
Due to the large variation in arthritis scores induced in the CIA mice and different responses 
to etanercept in individual mice, many animals had to be used per group. Despite this due the 
correlative figures show that these tracers can be used to objectively and quantitatively determine 
arthritis score in individual paws.  
For a review on general tracers and radiolabeled biologicals used to image inflammatory 
processes see Put et al. (30). Previous studies have focused mostly on targeting macrophages, either 
with radiolabeled folate (31-33), (R)-11C-PK11195 or translocator protein TSPO (34-36), which has 
also been used clinically, radiolabeled nanobodies (37), or by targeting CD163 receptors (38), or 
mannose receptors (39). Unfortunately, images acquired using radiolabeled folate led to poor 
quality images (31), most probably due to general low uptake of the tracers in the joints (32), a 
feature also seen with the anti-CRIg nanobody 99mTc-NbV4m119 (37). So far, the only tool to image 
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F4/80 receptors specifically has been near infrared-labeled antibodies (40), making our radiolabeled 
anti-F4/80-A3-1 antibody a unique nuclear tool. 
Other, more generalized ways of imaging arthritis include 18F-FLT (41), which showed high 
background levels due to uptake in bone marrow, and 18F-FDG. Despite the fact that 18F-FDG was 
suggested as a good tool to develop the therapeutic effect of novel therapies of inflammatory 
arthritis with (42), in a preclinical model Laverman et al. showed that 18F-FDG was inferior to other 
nuclear imaging tracers when correlating uptake of 18F-FDG  with arthritis score (8).  
Monitoring response to therapy in arthritis is usually carried out by clinical macroscopic 
scoring, ultrasonography, conventional radiography or MRI. Not only does this highlight the 
originality of the studies carried out here, by targeting integrins, macrophages or FAP in preclinical 
models of arthritis, but also the novelty of assessing these tracers as tools to monitor therapy 
response. Radionuclide imaging targeting specific molecular mechanisms could therefore be a great 
tool alongside the standard techniques, although cost:benefit analysis will need to be performed to 
determine whether any potential risk from radiation dose outweighs the benefits of early and quick 
therapy response monitoring. 
 
CONCLUSION 
In conclusion, 111In-28H1, 111In-anti-F4/80-A3-1, and 111In-RGD2 can be used to specifically 
monitor therapy response in experimental arthritis at the molecular level. Further studies however 
still need to be carried out to not only confirm that altered target expression is the cause of the 
diminished uptake of all three tracers, but also to determine whether these tracers could be used for 
early diagnosis of arthritis as well as whether they can be used to monitor response to other types of 
therapies. 
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FIGURE LEGENDS 
FIGURE 1 
Joint uptake of tracers in untreated or etanercept-treated CIA mice at 48 h (111In-28H1, 111In-
DP47GS; A, B), 24 h (111In-anti-F4/80, 111In-ratIgG2b; C, D) and 1 h p.i. (111In-RGD2 with/without 
excess unlabeled; E, F). Data are average ± standard deviation (n=7-10 mice/group (A-D) or 2 
mice/group (E-F), 4 joints per mouse (A, C, E)) or individual joints (n=14-20 mice/group, 4 joints per 
mouse; B, D, F). *(p≤0.05), **(p≤0.01), and ***(p≤0.001). 
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FIGURE 2 
3D SPECT/CT scans of etanercept-treated CIA mice 48 h p.i. of 111In-28H1 (A) and 111In-DP47GS (B). 
All images are scaled equally. Panel C represents the quantitative analysis of the SPECT images. Data 
are average ± standard deviation (n=3 mice/group, 4 joints/mouse). **(p≤0.01). 
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FIGURE 3 
3D SPECT/CT scans of etanercept-treated CIA mice 24 h p.i. of 111In-anti-F4/80 (A) and 111In-ratIgG2b 
(B). All images are scaled equally. Panel C represents the quantitative analysis of the SPECT images. 
Data are average ± standard deviation (n=3 mice/group, 4 joints/mouse). ***(p≤0.001). 
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FIGURE 4 
3D SPECT/CT scans of untreated CIA mice 1 h p.i. of 111In-RGD2 (A). Panel B represents the 
quantitative analysis of the SPECT images of joint uptake after injection of 111In-RGD2 in untreated or 
treated CIA mice. Data are average ± standard deviation (n=1-2 mice/group, 4 joints/mouse). 
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TABLE 1 
Mean and 95% coincidence intervals (CI) of arthritis:blood uptake ratios from Figures 1B, D, F to 
provide. Where no CIs are shown, data is from n=1. All values over 25 were excluded. 
 
Arthritis 
score 
  
In-111-28H1 
 
In-111-DP47GS 
 
(Control) 
  
In-111-anti-
F4/80-A3-1 
 
In-111-anti-
ratIgG2b 
(Control) 
  
In-111-RGD2 
 
cold excess 
RGD2 
(Control) 
0 
 
 5.0 
(2.7-7.3) 
0.3 
(0.3-0.4) 
 1.8 
(0.6-2.9) 
0.2 
(0.2-0.2) 
 3.5 
(2.9-4.1) 
2.0 
(1.2-2.8) 
0.25 
 4.8 
(1.8-7.7) 
0.5 
(0.1-0.9) 
 1.7 
(0.9-2.6) 
0.2 
(0.1-0.3) 
 3.9 
(0.1-7.7) 
2.0 
(-3.2-7.3) 
0.5 
 
8.9 5.8 (-65.7-77.3) 
 
1.6 no data 
 
no data no data 
0.75 
 
1.2 0.4 (-0.2-1.0) 
 
no data no data 
 
no data no data 
1 
 
no data 0.6 
 6.6 
(-29.4-42.5) no data 
 
no data 3.4 
1.25 
 11.8 
(-2.9-26.6) 
0.3 
(0.2-0.5) 
 7.1 
(3.2-11.1) 
0.4 
(0.1-0.8) 
 
no data no data 
1.5 
 8.3 
(1.9-14.7) 
2.2 
(-1.7-6.0) 
 6.4 
(5.3-7.5) 
0.5 
(0.4-0.7) 
 
8.2 3.8  (1.8-5.8) 
1.75 
 8.4 
(5.5-11.2) 
0.6 
(0.5-0.8) 
 7.6 
(6.4-8.9) 
0.5 
(0.4-0.5) 
 
8.1 3.1 
2 
 5.5 
(4.7-6.4) 
0.7 
(0.3-1.2) 
 10.4 
(7.9-13.0) 
0.5 
(0.4-0.6) 
 7.2 
(-5.9-20.3) 3.5 
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